Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.
A majority of people with alcohol-related liver cirrhosis may have normal ALT levels.
Abdominal obesity worsened the impact of air pollution on MAFLD development.
The PreHevbrio vaccine produces higher antibody levels and offers faster protection.
There are not enough words to describe my joy after being told I would be riding in the Tournament of Roses Parade with my organ donor.
Nearly 296 million people worldwide have hepatitis B. A new report and webinar explore how stigma impacts them—and which policies can help.
Fatty liver disease dominated the Hep science news this year, but COVID-19 remains a concern for people with liver disease.
People with fatty liver disease and obesity who underwent bariatric surgery had better clinical outcomes.
Hepatocellular carcinoma can still occur after hepatitis C is cured, and risk factors differ for people with and without cirrhosis.
Over the next two decades, obesity-linked NASH will lead to more deaths and high cost in the United States.
People with HIV had fewer cirrhosis-related complications but greater healthcare utilization.
Research has shown that elevated levels of iron in the blood from hereditary hemochromatosis can raise the risk of HCC.
Timely testing and treatment could improve outcomes for young people who inject drugs.
From 1995 to 2016, hepatocellular carcinoma incidence in rural populations climbed by 218%.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.